3 Latin America Branded Generics Seller, Research-Driven Pharma Company and Respiratory and Cardio Specialist Stocks With a Strong Future Roadmap: Caplin Point Laboratories, Glenmark Pharmaceuticals and Lupin
- October 27, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Caplin Point Laboratories, Glenmark Pharmaceuticals and Lupin: ROE of 17.9% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 15.2%. Prices as of 26 Oct 2026.
Quick Answer
The three Latin America and respiratory pharma stocks to watch are Caplin Point Laboratories, Glenmark Pharmaceuticals and Lupin. Their return on equity ranges from 17.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 15.2%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Caplin Point Laboratories has the fastest revenue growth at 15.2% a year. Prices are based on the 26 October 2026 close, and this article is educational, not investment advice.
Latin America and respiratory pharma stocks let investors follow companies that serve a growing part of the Indian economy. Caplin Point Laboratories, Glenmark Pharmaceuticals and Lupin cover a Latin America branded generics seller, a research-driven pharma company and a respiratory and cardio specialist.
This list covers three Latin America and respiratory pharma stocks with complete current figures: Caplin Point Laboratories, Glenmark Pharmaceuticals and Lupin. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Latin America and Respiratory Pharma Stocks?
Latin America and respiratory pharma stocks are listed drug makers that sell medicines in emerging markets, the United States and India across respiratory, skin and heart care. Their earnings depend on launches, approvals, plant quality and prescriptions.
Latin America and Respiratory Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Caplin Point Laboratories | 2,273.9 | 17,194 | 25.4 | 36.0 | 17.9 | 0.00 |
| Glenmark Pharmaceuticals | 2,225.8 | 60,103 | 33.4 | 35.7 | 28.1 | 0.06 |
| Lupin | 1,959.9 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing Latin America and respiratory pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in Latin America and respiratory pharma stocks can use the coming numbers to test whether growth is holding.
Why Do Latin America and Respiratory Pharma Stocks Have a Strong Roadmap in India?
Latin America and respiratory pharma stocks have a strong roadmap in India because a wide product pipeline, rising healthcare access and entry into regulated markets keep widening the revenue base.
- Emerging markets. Branded generics find steady buyers abroad.
- Complex generics. Harder products face fewer rivals.
- Respiratory care. Chronic therapy brands retain prescribers.
Why Caplin Point Laboratories Features Among These Latin America and Respiratory Pharma Stocks
Among the Latin America and respiratory pharma stocks on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.
In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%.
Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.
Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.
What to watch: Follow new US product approvals and currency trends in Latin American markets.
Why Glenmark Pharmaceuticals Features Among These Latin America and Respiratory Pharma Stocks
Among the Chennai pharma exporter and respiratory brand shares on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.
The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.
Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore.
Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.
Why Lupin Features Among These Latin America and Respiratory Pharma Stocks
Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%.
In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Caplin Point Laboratories vs Glenmark Pharmaceuticals vs Lupin on Key Financials
The table below sets the three Latin America and respiratory pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Caplin Point Laboratories | 1,308 | 2,303 | 15.2% | 650 | 28.2% |
| Glenmark Pharmaceuticals | 12,472 | 17,443 | 8.7% | 1,362 | 7.8% |
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Caplin Point Laboratories shows the fastest revenue growth with a 15.2% compound annual rate. A useful habit with Latin America and respiratory pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Caplin Point Laboratories | 533 | 644 | 20.7% |
| Glenmark Pharmaceuticals | 3,291 | 4,084 | 24.1% |
| Lupin | 6,347 | 8,407 | 32.5% |
Key Risks to Check Before Investing in Latin America and Respiratory Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these Latin America and respiratory pharma stocks, the main points are: Long-term Chennai pharma exporter and respiratory brand shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices abroad can fall.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter Latin America and respiratory pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Latin America and Respiratory Pharma Stocks
Latin America and respiratory pharma stocks reward investors who follow demand trends, order books and margins together. Caplin Point Laboratories, Glenmark Pharmaceuticals and Lupin each have a clear plan to grow. Based on the 26 October 2026 close, Caplin Point Laboratories trades at Rs 2,273.9, Glenmark Pharmaceuticals at Rs 2,225.8 and Lupin at Rs 1,959.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these Latin America and respiratory pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track Latin America and respiratory pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are Latin America and respiratory pharma stocks?
Ans. Latin America and respiratory pharma stocks are listed drug makers that sell medicines in emerging markets, the United States and India across respiratory, skin and heart care. Their earnings depend on launches, approvals, plant quality and prescriptions. This list looks at three of them, Caplin Point Laboratories, Glenmark Pharmaceuticals and Lupin, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.
Which Latin America and respiratory pharma stocks are covered in this list?
Ans. This list covers Caplin Point Laboratories, Glenmark Pharmaceuticals and Lupin. Based on the 26 October 2026 close, Caplin Point Laboratories traded at Rs 2,273.9, Glenmark Pharmaceuticals at Rs 2,225.8 and Lupin at Rs 1,959.9. Their return on equity ranges from 17.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 15.2%.
Why do Latin America and respiratory pharma stocks have a strong future roadmap in India?
Ans. Latin America and respiratory pharma stocks have a strong roadmap in India because a wide product pipeline, rising healthcare access and entry into regulated markets keep widening the revenue base. The main drivers are as follows. Emerging markets. Branded generics find steady buyers abroad. Complex generics. Harder products face fewer rivals. Respiratory care. Chronic therapy brands retain prescribers. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Caplin Point Laboratories performed financially?
Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.
How has Glenmark Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What risks should investors check before buying Latin America and respiratory pharma stocks?
Ans. Investors should check a few risks before buying Latin America and respiratory pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of Latin America and respiratory pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
